Latest news with #PAVmed
Yahoo
a day ago
- Business
- Yahoo
PAVmed subsidiary Veris Health partners with Ohio State University cancer center
PAVmed's (PAVM) majority-owned digital health subsidiary Veris Health has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, or OSUCCC – James, a National Cancer Institute-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Veris Cancer Care Platform. Veris and OSUCCC – James entered into a long-term, multi-project strategic partnership to utilize, and further the development and commercialization of the Veris Cancer Care Platform and its implantable physiologic monitor. The agreement includes expansion of commercial utilization of the platform across cancer care service lines; full electronic health record integration; initiation of a clinical registry of patients enrolled on the platform to be launched in the coming weeks; and launch of a clinical trial of patients receiving the implantable physiologic monitor, to be launched upon FDA clearance, expected next year. Cancer patients enrolled on the platform receive a VerisBox of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PAVM: Disclaimer & DisclosureReport an Issue Lucid Diagnostics to join Russell 2000, Russell 3000 indexes PAVmed's Earnings Call: Optimism Amid Challenges PAVmed's Strategic Advancements and Growth Potential Drive Buy Rating Pavmed Inc. Reports Turnaround with Strong Q1 Earnings PAVmed Reports Q1 2025 Financial Results and Updates
Associated Press
27-05-2025
- Business
- Associated Press
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ('Lucid' or the 'Company'), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. 'We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products,' said Dennis McGrath, Lucid's Chief Financial Officer. 'This important milestone is a testament to the significant progress Lucid has made in enhancing shareholder value over the past year. We are confident that it will increase our visibility and access to a broader range of institutional investors.' The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025, this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the 'Russell Reconstitution' section on the FTSE Russell website. About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information about Lucid, please visit and for more information about its parent company PAVmed, please visit About FTSE Russell FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, 'Risk Factors,' in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE Lucid Diagnostics
Yahoo
16-05-2025
- Business
- Yahoo
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. PAVmed Inc (NASDAQ:PAVM) has successfully stabilized its corporate structure and balance sheet, positioning itself as a diversified commercial life science company. The company reported a significant strengthening of its balance sheet with a public offering netting $16.1 million, extending its financial runway well into 2026. Lucid, a subsidiary of PAVmed Inc (NASDAQ:PAVM), is on the cusp of key milestones, including Medicare coverage, and reported revenue of $800,000 with test volumes at the upper end of their target range. PAVmed Inc (NASDAQ:PAVM) has secured financing to restart development of a critical implantable monitor for its subsidiary, Veris, and is close to finalizing a strategic partnership. The company is actively pursuing expansion into the biopharma space, leveraging its infrastructure and track record to explore attractive assets and partnerships. PAVmed Inc (NASDAQ:PAVM) faces uncertainties related to forward-looking statements, which are subject to risks that could cause actual results to differ materially. The company is still awaiting a response from the Medicare program regarding coverage for its e-cigarette diagnostic, which is crucial for accelerating commercialization. There are significant differences in financial reporting due to the deconsolidation of Lucid, which may blur historical understanding of PAVmed Inc (NASDAQ:PAVM)'s financials. The company has a complex corporate structure with multiple subsidiaries, which may pose challenges in management and strategic alignment. PAVmed Inc (NASDAQ:PAVM) is pursuing multiple initiatives simultaneously, including expansion into biopharma, which could stretch its resources and focus. Warning! GuruFocus has detected 8 Warning Signs with PAVM. Q: Now that the pilot program is complete, can you share any feedback from physicians and patients, and has this influenced any changes to the platform before commercialization? A: We've received excellent feedback, meeting all pre-specified performance metrics, including patient satisfaction and clinical success. There is significant enthusiasm, especially with the upcoming implantable monitor. No immediate changes to the platform are needed, but we've learned valuable lessons on implementation processes, which we are applying moving forward. (Respondent: Unidentified_6) Q: Does OSU have exclusive rights to the Veris platform, or are you in talks with other centers? A: OSU has some local rights but nothing that limits our broader commercialization efforts. We aim to use our strong relationship with OSU as a model to replicate at other cancer centers nationwide. (Respondent: Unidentified_6) Q: Can you elaborate on your expansion into the biopharma segment and the financing strategy for this venture? A: Our corporate structure and balance sheet adjustments have positioned us to explore new opportunities, including biopharma. We plan to leverage our infrastructure and track record to pursue attractive assets, particularly those struggling to raise private capital. Financing will follow our model of independently financed subsidiaries, similar to Lucid and Veris. (Respondent: Unidentified_6) Q: Has market volatility affected your ability to raise capital? A: No, we've been fortunate to attract investors aligned with our vision. Our recent financing activities demonstrate our ability to secure necessary funds, and we expect to continue accessing both private and public capital as needed. (Respondent: Unidentified_4) Q: What is the strategic rationale for expanding into biopharma now, given your existing commitments? A: Our structure allows us to pursue shareholder value across various sectors. The biopharma expansion is driven by opportunities identified with our board member, Dr. Sande Agarwal, and aligns with our history of leveraging infrastructure for new ventures. We believe this sector offers streamlined pathways to value creation. (Respondent: Unidentified_6) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
24-02-2025
- Business
- Associated Press
PAVmed and Subsidiary Veris Health Complete Private Placement Financing
Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK, Feb. 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ('PAVmed' or the 'Company') a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc, ('Veris') today announced that the companies have completed a $2.37 million private placement financing as detailed in Form 8-K filed with the SEC on February 21, 2025. Accredited investors purchased PAVmed securities priced at-the-market and shares of Veris common stock reflecting a pre-money Veris valuation of approximately $35 million. The financing supplements a recently secured $1.8 million non-dilutive two-year NIH grant and will fund development of Veris' implantable physiological monitor. 'This financing marks an important milestone which will allow Veris Health to advance its commercial strategy, including regulatory clearance and launch of its implantable physiological monitor,' said Lishan Aklog, M.D., Chairman and CEO of PAVmed and Executive Chairman of Veris Health. 'We believe the Veris pre-money valuation reflects strong investor confidence in Veris' long-term commercial potential as it seeks to enhance personalized cancer care through the early detection of complications and reduced unplanned hospitalizations. We expect that, once cleared and launched, the implantable monitor will significantly enhance this commercial potential.' About Veris Health Veris Health Inc. is a digital health company whose lead product, the Veris Cancer Care Platform, is a comprehensive digital care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction. Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via an embedded cellular connection. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted in combination with a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance. Cancer centers and oncology centers interested in learning more about Veris and the Veris Platform, please visit to contact a company representative. About PAVmed PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its other subsidiary (in addition to Veris), Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. For more and for more information about PAVmed, please visit For more information about Veris Health, please visit Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, 'Risk Factors,' in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
